Clinical Trial Update: A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial update reports immunogenicity and safety data for GlaxoSmithKline's HPV vaccine in healthy women aged 18-35, and the study has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Genital Warts
• Human Papillomavirus Infection

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 3 | Status: COMPLETED